CD53 and neoplasm: Using a human T cell line, gene-modified to express a tumor-specific CIR on their surface, and a human tumor cell line we demonstrated that combining CIR-mediated activation with FACS sorting of CD69+ T cells, it is possible to isolate binders to tumor specific cell surface antigen, with an enrichment factor of 103-fold after two rounds.